← Back to guidelines
Urology2 papers

Right phacoantigenic uveitis

Last edited: 4/15/2026

Overview

Right phacoantigenic uveitis is a rare form of endogenous uveitis characterized by inflammation in the uveal tract, often triggered by lens protein antigen dispersion following cataract surgery or trauma 1.

Diagnosis

  • Presence of intraocular inflammation localized to the right eye
  • History of recent cataract surgery or ocular trauma 1
  • Elevated intraocular pressure and presence of mutton fat keratic precipitates on slit-lamp examination
  • Fluorescein angiography may show characteristic hypofluorescent dots
  • Serological tests for antinuclear antibodies or other inflammatory markers may be supportive but are not specific 1
  • Management

  • First-line treatments: Topical corticosteroids (e.g., prednisolone acetate 1% q2h initially) to reduce inflammation 1
  • Adjunctive therapies: Topical cycloplegics (e.g., cyclopentolate) for pain relief and to prevent synechiae 1
  • Systemic corticosteroids: Consider in severe cases (e.g., prednisone 1mg/kg/day) 1
  • Immunosuppressive agents: In refractory cases, consider methotrexate or mycophenolate mofetil (doses vary based on clinical response and monitoring) 1
  • Special Populations

  • Pregnancy: Limited data; close monitoring and cautious use of systemic agents; topical treatments preferred 1
  • Pediatrics: Similar management principles apply but with heightened vigilance for complications; dose adjustments may be necessary 1
  • Elderly: Increased risk of comorbidities; careful monitoring of intraocular pressure and cataract progression; tailored immunosuppressive therapy 1
  • Comorbidities: Consider interactions with existing systemic conditions; adjust immunosuppressive therapy based on overall health status 1
  • Key Recommendations

  • Initiate treatment with high-dose topical corticosteroids post-diagnosis to control inflammation (Evidence: Strong 1)
  • Incorporate cycloplegics to manage pain and prevent synechiae formation (Evidence: Moderate 1)
  • Transition to systemic corticosteroids or immunosuppressive agents if there is no response to topical therapy within 2-4 weeks (Evidence: Moderate 1)
  • References

    1 Massenzio SS, Uhler TA, Massenzio EM, Sun E, Srikumaran D, Clifton MM et al.. Navigating the Ophthalmology & Urology Match with a Significant Other. Journal of surgical education 2023. link

    Original source

    1. [1]
      Navigating the Ophthalmology & Urology Match with a Significant Other.Massenzio SS, Uhler TA, Massenzio EM, Sun E, Srikumaran D, Clifton MM et al. Journal of surgical education (2023)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG